<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02352090</url>
  </required_header>
  <id_info>
    <org_study_id>SYLVI030785</org_study_id>
    <nct_id>NCT02352090</nct_id>
  </id_info>
  <brief_title>Synthetic vs Natural Estrogen in Combined Oral Contraception</brief_title>
  <acronym>SYLVI</acronym>
  <official_title>Synthetic vs Natural Estrogen in Combined Oral Contraception- Effect on Insulin Sensitivity, Coagulation, Inflammation and Endometrium - a Comparison With a Progestin-only Preparation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to compare the metabolic effects of natural estradiol and&#xD;
      synthetic ethinylestradiol used in combined oral contraception in healthy women. A&#xD;
      progestin-only preparation will be used in comparison. The main goal is to study the effects&#xD;
      on glucose metabolism, coagulation and a markers of chronic inflammation (such as hs-CRP).&#xD;
      Our hypothesis is that the natural estradiol preparation will influence blood glucose levels,&#xD;
      markers of coagulation and chronic inflammation less than the ethinylestradiol preparation.&#xD;
      The progestin-only preparation will not effect these parameters.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2015</start_date>
  <completion_date type="Actual">December 30, 2018</completion_date>
  <primary_completion_date type="Actual">December 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Matsuda Index- Whole Body Insulin Sensitivity Index</measure>
    <time_frame>We calculated the change in Matsuda index from baseline to 9 weeks.</time_frame>
    <description>Matsuda index is calculated from the standard 2h Oral Glucose Tolerance Test and corresponding insulin values.&#xD;
Matsuda index = 10,000/square root of [fasting glucose x fasting insulin] x [mean glucose x mean insulin during OGTT]) The Matsuda index is correlated (r = 0.73) with the rate of whole-body glucose disposal during the euglycemic insulin clamp.&#xD;
Matsuda index &lt;2.5 is considered insulin resistant, higher values indicate less insulin resistance. A decrease in matsuda index over the study period would indicate decreased insulin sensitivity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Insulin</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Mean change in fasting serum insulin from baseline to nine weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-sensitivity C Reactive Protein</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Change in plasma concentrations of acute phase protein 'C reactive protein' (CRP), a marker of chronic inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mononuclear Cell Interleukin 6 Secretion</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Change from baseline in mononuclear cell inflammatory response at 9 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nuclear Factor Kappa-light-chain-enhancer -Activation (NFkB-activation)</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Change from baseline in mononuclear cell inflammatory response at 9 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Change in concentrations of total cholesterol from baseline to nine weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low-Density Lipoprotein (LDL)</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Change in concentration of Low-Density Lipoprotein LDL from baseline to nine weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-Density Lipoprotein (HDL)</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Change in concentration of High-Density Lipoprotein HDL from baseline to nine weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Change in triglyceride concentrations from baseline to nine weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin Fragments 1+2</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Markers of coagulation activation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Change in plasma concentrations of D-dimer, a marker of fibrinolysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin Generation, ETP Endogenous Thrombin Potential</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Change from baseline in thrombin generation, measured by thrombin generation assay-Calibrated automated thrombogram</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Anti Mullerian Hormone (AMH)</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Change in Serum concentrations of anti-mullerian hormone reflecting ovarian reserve from baseline to nine weeks</description>
  </other_outcome>
  <other_outcome>
    <measure>Vaginal Bleeding</measure>
    <time_frame>9 weeks</time_frame>
    <description>Self-reported days of vaginal bleeding in bleeding diary.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patterns of Vaginal Bleeding</measure>
    <time_frame>9 weeks</time_frame>
    <description>Self- reported clusters of bleeding days in bleeding diary.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life Questionnaire (EQ-5D Questionnaire)</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Change from baseline in Quality of Life scores at 9 weeks</description>
  </other_outcome>
  <other_outcome>
    <measure>State-Trait Anxiety Inventory (STAI) Questionnaire</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Change from baseline in Anxiety scores at 9 weeks</description>
  </other_outcome>
  <other_outcome>
    <measure>Mccoy Female Sexuality Questionnaire (MFSQ) Questionnaire</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Change from baseline in sexuality scores at 9 weeks</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Synthetic estrogen + progestin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ethinyl estradiol / dienogest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Natural estrogen + progestin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Estradiol valerate / dienogest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progestin-Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dienogest</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethinyl estradiol / dienogest</intervention_name>
    <description>One tablet orally for 9 weeks, continuous use</description>
    <arm_group_label>Synthetic estrogen + progestin</arm_group_label>
    <other_name>Valette, ATC code G03AA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol valerate / dienogest</intervention_name>
    <description>One tablet orally for 9 weeks, continuous use</description>
    <arm_group_label>Natural estrogen + progestin</arm_group_label>
    <other_name>Qlaira, ATC code G03AB08</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dienogest</intervention_name>
    <description>One tablet orally for 9 weeks, continuous use</description>
    <arm_group_label>Progestin-Only</arm_group_label>
    <other_name>Visanne, ATC code G03D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI 19-24.9, regular menstrual cycles (21-35 days), a minimum of 2 months without any&#xD;
             hormonal contraceptives, no contraindications for use of hormonal contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Polycystic ovaries, hypertension, smoking, alcohol abuse, pregnancy, lactation,&#xD;
             abnormal result in pre-screening 2h oral glucose tolerance test, regular medications&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oskari Heikinheimo, Prof., PhD., MD.</last_name>
    <role>Study Chair</role>
    <affiliation>Helsinki University Central Hospital, Department of Gynecology and Obstetrics. Helsinki Univeristy, Medical Faculty</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juha Tapanainen, Prof., PhD, MD.</last_name>
    <role>Study Chair</role>
    <affiliation>Helsinki University Central Hospital, Department of Gynecology and Obstetrics. Helsinki Univeristy, Medical Faculty</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Terhi Piltonen, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oulu University Hospital, Department of Gynecology and Obstetrics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Annina Haverinen, MD, PhD student</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital, Department of Gynecology and Obstetrics. Helsinki University, Faculty of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital, Kätilöopisto Maternity Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital, Department of Gynecology and Obstetrics</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 20, 2015</study_first_submitted>
  <study_first_submitted_qc>January 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2015</study_first_posted>
  <results_first_submitted>April 16, 2021</results_first_submitted>
  <results_first_submitted_qc>June 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 29, 2021</results_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Annina Haverinen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Contraception, oral</keyword>
  <keyword>Ethinyl Estradiol</keyword>
  <keyword>Estradiol Valerate</keyword>
  <keyword>Dienogest</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Chronic inflammation</keyword>
  <keyword>Coagulation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dienogest</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Nandrolone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 21, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT02352090/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 21, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT02352090/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Synthetic Estrogen + Progestin</title>
          <description>Ethinyl estradiol / dienogest&#xD;
Ethinyl estradiol / dienogest: One tablet orally for 9 weeks, continuous use</description>
        </group>
        <group group_id="P2">
          <title>Natural Estrogen + Progestin</title>
          <description>Estradiol valerate / dienogest&#xD;
Estradiol valerate / dienogest: One tablet orally for 9 weeks, continuous use</description>
        </group>
        <group group_id="P3">
          <title>Progestin-Only</title>
          <description>Dienogest&#xD;
Dienogest: One tablet orally for 9 weeks, continuous use</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>general malaise</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-specified mild side-effects</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Synthetic Estrogen + Progestin</title>
          <description>Ethinyl estradiol / dienogest&#xD;
Ethinyl estradiol / dienogest: One tablet orally for 9 weeks, continuous use</description>
        </group>
        <group group_id="B2">
          <title>Natural Estrogen + Progestin</title>
          <description>Estradiol valerate / dienogest&#xD;
Estradiol valerate / dienogest: One tablet orally for 9 weeks, continuous use</description>
        </group>
        <group group_id="B3">
          <title>Progestin-Only</title>
          <description>Dienogest&#xD;
Dienogest: One tablet orally for 9 weeks, continuous use</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="17"/>
            <count group_id="B4" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.8" spread="3.8"/>
                    <measurement group_id="B2" value="24.1" spread="3.6"/>
                    <measurement group_id="B3" value="24.0" spread="3.9"/>
                    <measurement group_id="B4" value="24.6" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.3" spread="4.5"/>
                    <measurement group_id="B2" value="61.4" spread="5.8"/>
                    <measurement group_id="B3" value="58.0" spread="7.1"/>
                    <measurement group_id="B4" value="61.0" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.1" spread="1.9"/>
                    <measurement group_id="B2" value="22.4" spread="1.6"/>
                    <measurement group_id="B3" value="21.9" spread="1.9"/>
                    <measurement group_id="B4" value="22.5" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Matsuda Index- Whole Body Insulin Sensitivity Index</title>
        <description>Matsuda index is calculated from the standard 2h Oral Glucose Tolerance Test and corresponding insulin values.&#xD;
Matsuda index = 10,000/square root of [fasting glucose x fasting insulin] x [mean glucose x mean insulin during OGTT]) The Matsuda index is correlated (r = 0.73) with the rate of whole-body glucose disposal during the euglycemic insulin clamp.&#xD;
Matsuda index &lt;2.5 is considered insulin resistant, higher values indicate less insulin resistance. A decrease in matsuda index over the study period would indicate decreased insulin sensitivity.</description>
        <time_frame>We calculated the change in Matsuda index from baseline to 9 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Synthetic Estrogen + Progestin</title>
            <description>Ethinyl estradiol / dienogest&#xD;
Ethinyl estradiol / dienogest: One tablet orally for 9 weeks, continuous use</description>
          </group>
          <group group_id="O2">
            <title>Natural Estrogen + Progestin</title>
            <description>Estradiol valerate / dienogest&#xD;
Estradiol valerate / dienogest: One tablet orally for 9 weeks, continuous use</description>
          </group>
          <group group_id="O3">
            <title>Progestin-Only</title>
            <description>Dienogest&#xD;
Dienogest: One tablet orally for 9 weeks, continuous use</description>
          </group>
        </group_list>
        <measure>
          <title>Matsuda Index- Whole Body Insulin Sensitivity Index</title>
          <description>Matsuda index is calculated from the standard 2h Oral Glucose Tolerance Test and corresponding insulin values.&#xD;
Matsuda index = 10,000/square root of [fasting glucose x fasting insulin] x [mean glucose x mean insulin during OGTT]) The Matsuda index is correlated (r = 0.73) with the rate of whole-body glucose disposal during the euglycemic insulin clamp.&#xD;
Matsuda index &lt;2.5 is considered insulin resistant, higher values indicate less insulin resistance. A decrease in matsuda index over the study period would indicate decreased insulin sensitivity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.02" lower_limit="-2.51" upper_limit="0.46"/>
                    <measurement group_id="O2" value="-0.10" lower_limit="-1.34" upper_limit="1.14"/>
                    <measurement group_id="O3" value="-1.45" lower_limit="-3.22" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Insulin</title>
        <description>Mean change in fasting serum insulin from baseline to nine weeks</description>
        <time_frame>baseline and 9 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Synthetic Estrogen + Progestin</title>
            <description>Ethinyl estradiol / dienogest&#xD;
Ethinyl estradiol / dienogest: One tablet orally for 9 weeks, continuous use</description>
          </group>
          <group group_id="O2">
            <title>Natural Estrogen + Progestin</title>
            <description>Estradiol valerate / dienogest&#xD;
Estradiol valerate / dienogest: One tablet orally for 9 weeks, continuous use</description>
          </group>
          <group group_id="O3">
            <title>Progestin-Only</title>
            <description>Dienogest&#xD;
Dienogest: One tablet orally for 9 weeks, continuous use</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Insulin</title>
          <description>Mean change in fasting serum insulin from baseline to nine weeks</description>
          <units>mU/l</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="-0.45" upper_limit="3.24"/>
                    <measurement group_id="O2" value="1.02" lower_limit="-0.6" upper_limit="2.6"/>
                    <measurement group_id="O3" value="1.99" lower_limit="0.33" upper_limit="3.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High-sensitivity C Reactive Protein</title>
        <description>Change in plasma concentrations of acute phase protein 'C reactive protein' (CRP), a marker of chronic inflammation.</description>
        <time_frame>baseline and 9 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Synthetic Estrogen + Progestin</title>
            <description>Ethinyl estradiol / dienogest&#xD;
Ethinyl estradiol / dienogest: One tablet orally for 9 weeks, continuous use</description>
          </group>
          <group group_id="O2">
            <title>Natural Estrogen + Progestin</title>
            <description>Estradiol valerate / dienogest&#xD;
Estradiol valerate / dienogest: One tablet orally for 9 weeks, continuous use</description>
          </group>
          <group group_id="O3">
            <title>Progestin-Only</title>
            <description>Dienogest&#xD;
Dienogest: One tablet orally for 9 weeks, continuous use</description>
          </group>
        </group_list>
        <measure>
          <title>High-sensitivity C Reactive Protein</title>
          <description>Change in plasma concentrations of acute phase protein 'C reactive protein' (CRP), a marker of chronic inflammation.</description>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" lower_limit="0.05" upper_limit="2.15"/>
                    <measurement group_id="O2" value="-0.06" lower_limit="-0.54" upper_limit="0.42"/>
                    <measurement group_id="O3" value="0.13" lower_limit="-0.22" upper_limit="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mononuclear Cell Interleukin 6 Secretion</title>
        <description>Change from baseline in mononuclear cell inflammatory response at 9 weeks</description>
        <time_frame>baseline and 9 weeks</time_frame>
        <posting_date>12/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nuclear Factor Kappa-light-chain-enhancer -Activation (NFkB-activation)</title>
        <description>Change from baseline in mononuclear cell inflammatory response at 9 weeks</description>
        <time_frame>baseline and 9 weeks</time_frame>
        <posting_date>12/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol</title>
        <description>Change in concentrations of total cholesterol from baseline to nine weeks</description>
        <time_frame>baseline and 9 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Synthetic Estrogen + Progestin</title>
            <description>Ethinyl estradiol / dienogest&#xD;
Ethinyl estradiol / dienogest: One tablet orally for 9 weeks, continuous use</description>
          </group>
          <group group_id="O2">
            <title>Natural Estrogen + Progestin</title>
            <description>Estradiol valerate / dienogest&#xD;
Estradiol valerate / dienogest: One tablet orally for 9 weeks, continuous use</description>
          </group>
          <group group_id="O3">
            <title>Progestin-Only</title>
            <description>Dienogest&#xD;
Dienogest: One tablet orally for 9 weeks, continuous use</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol</title>
          <description>Change in concentrations of total cholesterol from baseline to nine weeks</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" lower_limit="-0.18" upper_limit="0.38"/>
                    <measurement group_id="O2" value="-0.16" lower_limit="-0.33" upper_limit="0.02"/>
                    <measurement group_id="O3" value="0.11" lower_limit="-0.11" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Low-Density Lipoprotein (LDL)</title>
        <description>Change in concentration of Low-Density Lipoprotein LDL from baseline to nine weeks</description>
        <time_frame>baseline and 9 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Synthetic Estrogen + Progestin</title>
            <description>Ethinyl estradiol / dienogest&#xD;
Ethinyl estradiol / dienogest: One tablet orally for 9 weeks, continuous use</description>
          </group>
          <group group_id="O2">
            <title>Natural Estrogen + Progestin</title>
            <description>Estradiol valerate / dienogest&#xD;
Estradiol valerate / dienogest: One tablet orally for 9 weeks, continuous use</description>
          </group>
          <group group_id="O3">
            <title>Progestin-Only</title>
            <description>Dienogest&#xD;
Dienogest: One tablet orally for 9 weeks, continuous use</description>
          </group>
        </group_list>
        <measure>
          <title>Low-Density Lipoprotein (LDL)</title>
          <description>Change in concentration of Low-Density Lipoprotein LDL from baseline to nine weeks</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" lower_limit="-0.41" upper_limit="0.08"/>
                    <measurement group_id="O2" value="-0.14" lower_limit="-0.31" upper_limit="0.04"/>
                    <measurement group_id="O3" value="0.01" lower_limit="-0.19" upper_limit="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High-Density Lipoprotein (HDL)</title>
        <description>Change in concentration of High-Density Lipoprotein HDL from baseline to nine weeks</description>
        <time_frame>baseline and 9 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Synthetic Estrogen + Progestin</title>
            <description>Ethinyl estradiol / dienogest&#xD;
Ethinyl estradiol / dienogest: One tablet orally for 9 weeks, continuous use</description>
          </group>
          <group group_id="O2">
            <title>Natural Estrogen + Progestin</title>
            <description>Estradiol valerate / dienogest&#xD;
Estradiol valerate / dienogest: One tablet orally for 9 weeks, continuous use</description>
          </group>
          <group group_id="O3">
            <title>Progestin-Only</title>
            <description>Dienogest&#xD;
Dienogest: One tablet orally for 9 weeks, continuous use</description>
          </group>
        </group_list>
        <measure>
          <title>High-Density Lipoprotein (HDL)</title>
          <description>Change in concentration of High-Density Lipoprotein HDL from baseline to nine weeks</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" lower_limit="0.09" upper_limit="0.31"/>
                    <measurement group_id="O2" value="-0.02" lower_limit="-0.11" upper_limit="0.07"/>
                    <measurement group_id="O3" value="-0.02" lower_limit="-0.11" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglyceride</title>
        <description>Change in triglyceride concentrations from baseline to nine weeks</description>
        <time_frame>baseline and 9 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Synthetic Estrogen + Progestin</title>
            <description>Ethinyl estradiol / dienogest&#xD;
Ethinyl estradiol / dienogest: One tablet orally for 9 weeks, continuous use</description>
          </group>
          <group group_id="O2">
            <title>Natural Estrogen + Progestin</title>
            <description>Estradiol valerate / dienogest&#xD;
Estradiol valerate / dienogest: One tablet orally for 9 weeks, continuous use</description>
          </group>
          <group group_id="O3">
            <title>Progestin-Only</title>
            <description>Dienogest&#xD;
Dienogest: One tablet orally for 9 weeks, continuous use</description>
          </group>
        </group_list>
        <measure>
          <title>Triglyceride</title>
          <description>Change in triglyceride concentrations from baseline to nine weeks</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" lower_limit="0.35" upper_limit="0.56"/>
                    <measurement group_id="O2" value="0.18" lower_limit="0.01" upper_limit="0.35"/>
                    <measurement group_id="O3" value="0.06" lower_limit="-0.04" upper_limit="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prothrombin Fragments 1+2</title>
        <description>Markers of coagulation activation</description>
        <time_frame>baseline and 9 weeks</time_frame>
        <posting_date>10/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>D-dimer</title>
        <description>Change in plasma concentrations of D-dimer, a marker of fibrinolysis</description>
        <time_frame>baseline and 9 weeks</time_frame>
        <posting_date>10/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Thrombin Generation, ETP Endogenous Thrombin Potential</title>
        <description>Change from baseline in thrombin generation, measured by thrombin generation assay-Calibrated automated thrombogram</description>
        <time_frame>baseline and 9 weeks</time_frame>
        <posting_date>10/2021</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Anti Mullerian Hormone (AMH)</title>
        <description>Change in Serum concentrations of anti-mullerian hormone reflecting ovarian reserve from baseline to nine weeks</description>
        <time_frame>baseline and 9 weeks</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Vaginal Bleeding</title>
        <description>Self-reported days of vaginal bleeding in bleeding diary.</description>
        <time_frame>9 weeks</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patterns of Vaginal Bleeding</title>
        <description>Self- reported clusters of bleeding days in bleeding diary.</description>
        <time_frame>9 weeks</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Quality of Life Questionnaire (EQ-5D Questionnaire)</title>
        <description>Change from baseline in Quality of Life scores at 9 weeks</description>
        <time_frame>baseline and 9 weeks</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>State-Trait Anxiety Inventory (STAI) Questionnaire</title>
        <description>Change from baseline in Anxiety scores at 9 weeks</description>
        <time_frame>baseline and 9 weeks</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mccoy Female Sexuality Questionnaire (MFSQ) Questionnaire</title>
        <description>Change from baseline in sexuality scores at 9 weeks</description>
        <time_frame>baseline and 9 weeks</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 weeks. During the study period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Synthetic Estrogen + Progestin</title>
          <description>Ethinyl estradiol / dienogest&#xD;
Ethinyl estradiol / dienogest: One tablet orally for 9 weeks, continuous use</description>
        </group>
        <group group_id="E2">
          <title>Natural Estrogen + Progestin</title>
          <description>Estradiol valerate / dienogest&#xD;
Estradiol valerate / dienogest: One tablet orally for 9 weeks, continuous use</description>
        </group>
        <group group_id="E3">
          <title>Progestin-Only</title>
          <description>Dienogest&#xD;
Dienogest: One tablet orally for 9 weeks, continuous use</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Oskari Heikinheimo</name_or_title>
      <organization>Helsinki University Central Hospital</organization>
      <phone>+358 50 4271533</phone>
      <email>oskari.heikinheimo@helsinki.fi</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

